Founder mutations and the high prevalence of myotonia congenita in northern Finland
- PMID: 10430417
- DOI: 10.1212/wnl.53.2.297
Founder mutations and the high prevalence of myotonia congenita in northern Finland
Abstract
Objective and background: To find an explanation at the molecular level for the high prevalence of myotonia congenita in northern Finland and the exceptional pattern of inheritance of the disease in many families, and to study genotype-phenotype correlation in the patients.
Methods: Forty-six patients with myotonia congenita and 16 unaffected relatives from 24 families were studied. All 23 exons and their flanking regions of the gene for the chloride channel protein (ClC-1) were sequenced from at least one patient from all families.
Results: There were three different mutations of ClC-1 in the patients: one in exon 11, a T-to-G transversion that resulted in the substitution of cysteine for phenylalanine at amino acid position 413 (F413C); one in exon 15, a C-to-T transition that resulted in the substitution of valine for alanine at amino acid position 531 (A531V); and one in exon 23, a C-to-T transition that resulted in the substitution of a stop codon for an arginine codon at amino acid position 894 (R894X).
Conclusions: Molecular studies showed that even in families with apparent dominant inheritance, the actual mode of inheritance was autosomal recessive. This was explained not only by the observed consanguinity in some families but by an enrichment of three different mutations of the ClC-1 gene and a consequent high number of compound heterozygotes in the population. One of the mutations is unique to northern Finland. The conspicuous enrichment of the mutations is likely due to the founder effect and isolation by distance, as in other diseases in the Finnish heritage.
Similar articles
-
Spectrum of CLCN1 mutations in patients with myotonia congenita in Northern Scandinavia.Eur J Hum Genet. 2001 Dec;9(12):903-9. doi: 10.1038/sj.ejhg.5200736. Eur J Hum Genet. 2001. PMID: 11840191
-
Myotonia congenita in northern Finland: an epidemiological and genetic study.J Med Genet. 1998 Apr;35(4):293-6. doi: 10.1136/jmg.35.4.293. J Med Genet. 1998. PMID: 9598722 Free PMC article.
-
Truncating CLCN1 mutations in myotonia congenita: variable patterns of inheritance.Muscle Nerve. 2014 Apr;49(4):593-600. doi: 10.1002/mus.23976. Epub 2013 Sep 20. Muscle Nerve. 2014. PMID: 23893571
-
Physiology and pathophysiology of CLC-1: mechanisms of a chloride channel disease, myotonia.J Biomed Biotechnol. 2011;2011:685328. doi: 10.1155/2011/685328. Epub 2011 Dec 1. J Biomed Biotechnol. 2011. PMID: 22187529 Free PMC article. Review.
-
Myotonia congenita.Adv Genet. 2008;63:25-55. doi: 10.1016/S0065-2660(08)01002-X. Adv Genet. 2008. PMID: 19185184 Review.
Cited by
-
The Cullin 4A/B-DDB1-Cereblon E3 Ubiquitin Ligase Complex Mediates the Degradation of CLC-1 Chloride Channels.Sci Rep. 2015 May 29;5:10667. doi: 10.1038/srep10667. Sci Rep. 2015. PMID: 26021757 Free PMC article.
-
Consanguinity, endogamy, and genetic disorders in Tunisia.J Community Genet. 2013 Apr;4(2):273-84. doi: 10.1007/s12687-012-0128-7. Epub 2012 Dec 4. J Community Genet. 2013. PMID: 23208456 Free PMC article. No abstract available.
-
Myotonia-related mutations in the distal C-terminus of ClC-1 and ClC-0 chloride channels affect the structure of a poly-proline helix.Biochem J. 2007 Apr 1;403(1):79-87. doi: 10.1042/BJ20061230. Biochem J. 2007. PMID: 17107341 Free PMC article.
-
Myotonia congenita: mutation spectrum of CLCN1 in Spanish patients.J Genet. 2019 Sep;98:71. J Genet. 2019. PMID: 31544778
-
Suppressor tRNA in gene therapy.Sci China Life Sci. 2024 Oct;67(10):2120-2131. doi: 10.1007/s11427-024-2613-y. Epub 2024 Jun 24. Sci China Life Sci. 2024. PMID: 38926247 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources